Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Consistent with its relatively narrow host species range, hepatitis A virus (HAV) cannot infect C57BL/6 mice. However, in Mavs-/- mice with genetic deficiency of the innate immune signaling adaptor MAVS, HAV replicates robustly in the absence of disease. The HAV 3ABC protease cleaves MAVS in human cells, thereby disrupting virus-induced IFN responses, but it cannot cleave murine MAVS (mMAVS) due to sequence differences at the site of scission. Here, we sought to elucidate the role of 3ABC MAVS cleavage in determining HAV pathogenesis and host species range.</AbstractText>METHODS: <AbstractText Label="METHODS">Using CRISPR/Cas9 gene editing, we established two independent lineages of C57BL/6 mice with knock-in mutations altering two amino acids in mMAVS ('mMAVS-VS'), rendering it susceptible to 3ABC cleavage without loss of signaling function. We challenged homozygous Mavsvs/vs mice with HAV, and compared infection outcomes with C57BL/6 and genetically deficient Mavs-/- mice.</AbstractText>RESULTS: <AbstractText Label="RESULTS">The humanized murine mMAVS-VS protein was cleaved as efficiently as human MAVS when co-expressed with 3ABC in Huh-7 cells. In embyronic fibroblasts from Mavsvs/vs mice, mMAVS-VS was cleaved by ectopically expressed 3ABC, significantly disrupting Sendai virus-induced IFN responses. However, in contrast to Mavs-/- mice with genetic MAVS deficiency, HAV failed to establish infection in Mavsvs/vs mice, even with additional genetic knockout of Trif or Irf1. Nonetheless, when crossed with permissive Ifnar1-/- mice lacking type I IFN receptors, Mavsvs/vsIfnar1-/- mice demonstrated enhanced viral replication coupled with significant reductions in serum alanine aminotransferase, hepatocellular apoptosis, and intrahepatic inflammatory cell infiltrates compared with Ifnar1-/- mice.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">MAVS cleavage by 3ABC boosts viral replication and disrupts disease pathogenesis, but it is not by itself sufficient to break the host-species barrier to HAV infection in mice.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS">The limited host range of human hepatitis viruses could be explained by species-specific viral strategies that disrupt innate immune responses. Both hepatitis A virus (HAV) and hepatitis C virus express viral proteases that cleave the innate immune adaptor protein MAVS, in human but not mouse cells. However, the impact of this immune evasion strategy has never been assessed in vivo. Here we show that HAV 3ABC protease cleavage of MAVS enhances viral replication and lessens liver inflammation in mice lacking interferon receptors, but that it is insufficient by itself to overcome the cross-species barrier to infection in mice. These results enhance our understanding of how hepatitis viruses interact with the host and their impact on innate immune responses.</AbstractText>

The Q41R mutation in the HCV-protease enhances the reactivity towards MAVS by suppressing non-reactive pathways

Kinetics of hepatitis C virus NS3/4A-mediated MAVS cleavage during hepatitis C virus infection

Mechanism of Flexibility Control for ATP Access of Hepatitis C Virus NS3 Helicase.

Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations

MicroRNA-33/33* Inhibit the Activation of MAVS Through AMPK in Antiviral Innate Immunity

Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598

Limited Effect on NS 3 – NS 4 A Protein Cleavage after Alanine Substitutions Within the Immunodominant HLA-A 2-Restricted Epitope of the Hepatitis C Virus Genotype 3 a Non-Structural 3 / 4 A Protease

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity

Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis

Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model

Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection

Palmitoylation acts as a checkpoint for MAVS aggregation to promote antiviral innate immune responses

Genome-Wide CRISPR/Cas9 Screening Identifies That Mitochondrial Solute Carrier SLC25A23 Attenuates Type I IFN Antiviral Immunity Via Interfering with MAVS Aggregation.

Mutations in the NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon alpha-2a and ribavirin combination therapy

Ser235 phosphorylation of hepatitis C virus NS5A is required for NS5A dimerization and drug resistance

Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents

The protein arginine methyltransferase PRMT9 attenuates MAVS activation through arginine methylation

MAVS Forms Functional Prion-like Aggregates to Activate and Propagate Antiviral Innate Immune Response

Stimulation of Hepatitis C Virus (HCV) Nonstructural Protein 3 (NS3) Helicase Activity by the NS3 Protease Domain and by HCV RNA-dependent RNA Polymerase.